RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Sinocare’s shares started their second day of surging today after the Chinese firm said that its Covid-19 antibody test kit got the green light to be sold in the US.
Sinocare’s stock price [SHE: 300298] climbed by the daily limit of 10 percent to CNY19.93 (USD2.80) soon after the opening bell. The stock had risen over 9 percent yesterday.
The company completed product registration in the States but the impact on its business performance is uncertain due to possible changes in the domestic and foreign market environments amid the pandemic, the Changsha-based maker of diagnostic tools said in a statement yesterday.
Founded in 2002, Sinocare’s main products include blood glucose testing equipment.
Source: Yicai Global
